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Introduction 
The use of opioids has increased significantly in the last decade. Concern for the 
undertreatment of pain emerged in the mid-1990s, prompting providers to treat pain as a fifth 
vital sign. The pharmaceutical industry marketed their products as having significantly less abuse 
potential than reality. Prescriptions for pain medications soared with prescription opioids leading 
the way. Prescription opioids became ubiquitous in medicine cabinets and reports of abuse rose. 
Casually administered, illicit sale, theft, and doctor shopping became more common as reports of 
overdose also rose. By 2010, the United States government was issuing strategies to combat the 
opioid crisis.1  
People from all demographics were affected by the opioid crisis, including pregnant 
women and their fetuses. Use of opioids during pregnancy can lead to many complications, 
including neonatal abstinence syndrome (NAS) which results when an infant suffers withdrawal 
after cessation of gestational exposure to addictive substances like opioids. 2 Opioid agonist 
therapy (OAT) has long been the recommended treatment of choice for pregnant women with 
opioid use disorder (OUD).3 However, the use of opioids to combat the poor outcomes of opioids 
seems counterproductive. This study aims to explore if the use of medically assisted withdrawal 
and opioid detoxification are as effective as OAT in improving outcomes for fetuses born to 
women who were addicted to opiates during pregnancy.  
Background  
Methadone 
 Methadone is a long-acting, high-affinity, full mu-opioid receptor agonist that prevents 
withdrawal symptoms while limiting euphoric side effects.3 The typical length of effect is 24 
hours or longer. It is available as oral solution, tablet, or injectable solution.4 
Methadone drug therapy is recommended to be initiated as early in the pregnancy as 
possible to maximize fetal outcomes. Due to potential for serious side effects, hospitalization is 
suggested during initiation. Unlike buprenorphine, there is no need for withdrawal symptoms 
before starting therapy. The starting dose varies according to the symptoms of the patient; 
however, the typical dose is 20 to 30 milligrams (mg). Incremental titration of 5 to 10 mg every 
three hours may be performed as needed according to withdrawal symptoms on the first day. Day 
two dosing is the equivalent of the sum of the previous day’s dosing. If withdrawal symptoms 
are observed, the dose may be increased until no additional increases are needed to prevent 
withdrawal. Stabilization may require a week or more with the possibility of continued dose 
adjustment. Once stabilized, the patient may be discharged, and care is continued at outpatient 
treatment centers.4 
 Methadone administration is tightly controlled. Opioid treatment programs manage the 
daily dosing of methadone. Administration of the drug is conducted using the oral solution form 
so it can be observed, and diversion or misuse can be minimized. Office setting or at-home 
administration is not practiced.5 The physiological changes of pregnancy may require dose 
adjustments which can be managed by addiction specialists at treatment centers.3 Average 
maintenance dosing is 120 mg per day with evidence indicating better outcomes for those who 
are dosed at higher daily amounts.4 According to the American College of Obstetricians and 
Gynecologists (ACOG), methadone dose has no correlation with incidence or duration of NAS.3  
A significant portion of women enrolled in methadone programs continue to abuse 
substances during pregnancy, requiring high index of suspicion for polysubstance use. Drug 
monitoring is conducted by weekly urine drug testing. The urine drug screen-9 will test for 
methadone and other naturally occurring opioids, but not synthetic opioids such as 
buprenorphine or fentanyl which may need to be ordered separately. Index of suspicion for 
polysubstance use should remain high due to its role in reducing the benefits of OAT and 
increasing harm to the fetus.4  
Buprenorphine 
Buprenorphine is a partial mu-opioid receptor agonist that was approved for use in 2002.6 
It has a high affinity for the receptor, meaning it binds stronger to but with lower activity than 
full opioid agonists such as heroin, morphine, or methadone resulting in similar pharmacologic 
effects but with a ceiling effect at high doses. This results in lowered risk of adverse side effects 
such as respiratory depression, overdose, and death. Typical administration is done sublingually 
or buccally due to greater bioavailability as compared to oral administration.4 Buprenorphine is 
available as a monoproduct or in combination with naloxone, an opioid antagonist that is used to 
counteract symptoms of opioid overdose. The purpose of naloxone is to deter users from 
injecting the drug in order to achieve a greater euphoric effect or diverting the drug so others can 
do the same. Naloxone has no effect if taken sublingually, buccally, or orally but will have full 
effect if injected. Concern for possible adverse side effects of naloxone on the fetus has 
influenced discouragement of use of the combination product in pregnant patients5, however 
recent guidance from ACOG has indicated that naloxone may have no adverse effects and may 
be safe for use in pregnancy as time goes on and more data are collected.3  
 Initiation of buprenorphine treatment may lead to withdrawal symptoms, particularly if 
the patient has been exposed to opioids recently. It should be initiated when the patient shows 
signs of moderate withdrawal: chills alternating with flushing or diaphoresis, nausea, yawning, 
anorexia, lacrimation, rhinorrhea, or moderate muscle or joint aches. The effects of 
buprenorphine last from 24 to 48 hours, resulting in once daily or every other day dosing. Initial 
dosing is typically 2 to 4 mg with titration of an additional 2 to 8 mg after two hours of 
observation if withdrawal symptoms persist. Day two dosing is the equivalent of the sum of the 
previous day’s dosing. If withdrawal symptoms are observed, the dose may be increased in 4 mg 
increments for a maximum daily dose of 16 mg. Dosing for the average patient stabilizes at 8 to 
16 mg per day with possible need to adjust the dosing throughout pregnancy.4 Due to its partial 
agonist action, increasing the dose to more than 32 mg may not add to its efficacy.7 
Dispensation and monitoring of buprenorphine differ from methadone. Though 
buprenorphine may be administered through opioid treatment programs like methadone, it can 
also be dispensed through office-based means by trained U.S. Drug Enforcement 
Administration-approved providers. Weekly or monthly prescriptions are possible.5 Monitoring 
is conducted by urine drug testing with buprenorphine and/or its metabolite norbuprenorphine 
specified on the order. Frequency determined clinically.4 
Naltrexone 
 Naltrexone is an opioid antagonist. It competitively binds to opioid receptor sites with the 
highest affinity for mu-opioid receptors, blocking the euphoric effects of opioids and reducing 
craving which aid in abstinence efforts.8 Its forms include oral and injectable. The oral form has 
demonstrated poor adherence with no efficacy over placebo. Intramuscular naltrexone is long-
acting and is effective for four weeks.9 Currently, there is limited research on the effects of 
naltrexone on the fetus and pregnancy outcomes and guidance is to determine treatment on a 
case by case basis. A woman currently on naltrexone should be counseled on the limited safety 
data of the effects of naltrexone on the fetus if she chooses to continue treatment as well as the 
risk of relapse if she chooses to discontinue treatment to pursue complete detoxification.3 
Initiation of therapy requires an opioid-free period of at least seven to 10 days in order to avoid 
full withdrawal upon administration of the drug, which could cause harm through fetal stress or 
relapse.8  
Opioid Detoxification 
 Neonatal abstinence syndrome is a big motivator for the use of opioid detoxification 
during pregnancy. Successful detoxification results in no opiates in the mother’s system which 
would prevent NAS from occurring after birth. This has been attempted through residential 
treatment programs, incarceration, involuntary institutionalization, and individually without any 
medical supervision.10 Rates of relapse are high with one study showing at 96% positive urine 
toxicology at delivery as well as reports of postpartum maternal death due to overdose.10 Slow 
tapering off opioid maintenance treatment (buprenorphine or methadone) during pregnancy to 
reach complete detoxification has similarly shown relapse and the necessary return to some level 
of the previous treatment.11 Though detoxification is attractive, it will most likely result in the 
risk of NAS due to withdrawal.  
Neonatal Abstinence Syndrome 
 Neonatal abstinence syndrome is a constellation of symptoms experienced by the 
newborn while undergoing withdrawal due to the abrupt discontinuation of opioids upon birth. 
Gestational exposure to such substances as methadone, buprenorphine, cocaine, 
benzodiazepines, alcohol, nicotine, and other opioid-containing drugs like fentanyl, 
hydrocodone, or oxycodone can result in NAS. Additionally, other factors may contribute to the 
presentation of NAS such as polysubstance abuse, maternal psychiatric comorbidities, exposure 
to violence and other maternal stressors, inadequate nutrition, and poor prenatal care.12 Though 
rarely fatal, complications of NAS can cause illness and subsequent prolonged hospital stays.2  
 The clinical presentation of NAS can be varied. The infant may display emphasis of one 
or a few symptoms with little or no expression of others, or they may display each symptom. The 
specific symptoms include hyperirritability, excessive high-pitched crying, exaggerated Moro 
reflex, myoclonic jerks, hypertonicity, tremors, poor sleep, uncoordinated sucking reflexes, 
gastrointestinal disturbances, and autonomic disturbances such as fever, sweating, sneezing, and 
yawning. Not all symptoms are immediately obvious. Infants whose symptoms are primarily 
autonomic will be more subtle to detection and require more astute observation. In these cases, 
diagnosis is further complicated by a less pronounced response to treatment.12  
 Neonatal abstinence syndrome symptoms generally start within the first 72 hours of life 
for infants exposed to methadone and last for several days to weeks. Infants exposed to 
buprenorphine, NAS symptoms usually appear within 12 to 48 hours and last for seven days. 
Currently, the modified Finnegan Scoring System is the most commonly used tool to diagnose 
NAS. Neonates are observed for various central nervous, gastrointestinal, and autonomic 
disturbances every three to four hours while awake after feeding. Typically, a score of above 
eight is considered pathological and requires pharmacological treatment, however that score may 
vary according to the institution.13 Diagnosis is clinical, but toxicological confirmation may be 
necessary to rule in or out other substances that may have been present during pregnancy. This 
may be done with meconium or urine testing.2  
 Treatment for NAS can be both pharmacological and nonpharmacological. 
Nonpharmacological treatment consists of soothing techniques and manipulation of the 
environment to calm the mother and infant.12 Transfer of methadone or buprenorphine into breast 
milk is minimal regardless of dose, therefore breastfeeding is indicated for mothers who are 
stable on their opioid agonist, are not abusing illicit or licit drugs, and are not infected with 
human immunodeficiency virus (HIV). It has been associated with lowered severity of NAS 
symptoms in infants, shorter hospital stays, and a lowered need for pharmacotherapy.3 
Pharmacological treatment is indicated when signs and symptoms are not controlled, 
severe dehydration results from withdrawal, serious side effects occur such as seizures, or 
Finnegan scores remain high. The goal of treatment is to reduce severity of NAS symptoms to a 
level that allows for the infant to eat, sleep, and interact.12 The most common agent used is 
morphine. Its short half-life requires frequent dosing, but dose adjustment can be made quickly if 
necessary. However, weaning must be done slowly. Hospital stays may be prolonged if morphine 
is used. Methadone is another option. Unlike morphine, it is dosed twice daily due to its long 
half-life, making it difficult to titrate. Buprenorphine is a newer alternative but lacks enough data 
to support its use. Adjuvants include phenobarbital or clonidine.2 
Methods 
 PubMed was searched between May 24, 2019 and July 22, 2019. Keywords included in 
the search were: pregnancy, opioids, buprenorphine, methadone, naltrexone, detoxification, 
neonatal abstinence syndrome, and OUD. Studies that were included were in English, contained 
information pertaining to human studies, and focused on pregnant women using OAT or 
detoxification and neonatal outcomes.  
Discussion 
Opioid Agonist Therapy Alternatives 
 Opioid detoxification is an option that is ideal in theory, but difficult to execute in 
practice. The goal is to decrease the chances of NAS and therefore decreasing the lengths of 
hospital stays and associated negative outcomes for the infant. Successful detoxification has been 
linked to absence of NAS, higher birth weights in comparison to those with ongoing illicit drug 
use, preterm birth rates and fetal loss comparable to the general population, and normal physical 
development. However, the studies showing these outcomes had high variability with fair to poor 
overall quality of evidence. Accurate interpretation of the data was limited due to the 
retrospective studies and lack of randomized controls.12  
NAS is a painful consequence of opioid use. It is painful for the neonate to suffer through 
and witnessing can induce feelings of guilt and anxiety in the mother. This can lead to high rates 
of relapse, which is harmful for the health of the mother as well as contribute to poor outcomes 
for her infant. Relapse rates were high in most studies, resulting in continued gestational opioid 
exposure and increased risk of HIV and hepatitis infection; some studies reported maternal death 
due to overdose in the postpartum period. Behavioral therapy and ongoing support are crucial to 
success throughout the perinatal and postpartum periods. In addition to high relapse rates, fetal 
stress in response to maternal withdrawal has limited data but remains a high concern that should 
be discussed with every potential candidate for detoxification. Current evidence indicates there is 
not enough data to support detoxification as a superior option to OAT.12 
Naltrexone, an opioid antagonist, is another alternative to OAT. It is not an opioid, thus 
NAS and its associated neonatal outcomes such as low birth weight and extended hospital stays 
are decreased in comparison to mothers treated with OAT if it is utilized faithfully. However, in 
the study conducted by Kelty and Hulse, NAS was not eliminated. This was attributed to the 
mother relapsing during pregnancy. The study did not find an association between naltrexone 
and perinatal mortality or neonatal mortality. Rates of congenital birth abnormalities are 
comparable to the general population; however, rates of urogenital abnormalities are higher.14 
Given these positive outcomes, naltrexone seems a superior option, but consideration must be 
given to the process of initiation of treatment. If the woman is not already on naltrexone at the 
time of pregnancy, an opioid-free period of seven to 10 days is required, and she must exhibit 
signs of withdrawal prior to initiation.8 This period is problematic for its high risk of relapse as 
well as the limited data on the effect of maternal withdrawal on the fetus. Current naltrexone use 
and the reliability of the woman must be heavily weighed when considering naltrexone as a 
means of opioid avoidance maintenance during pregnancy. Attempts at detoxification should be 
counseled against.3  
Opioid Agonist Therapy 
Methadone has been studied extensively and has been the medication of choice for opioid 
addiction therapy for over 40 years. It has been shown to be highly effective in treating OUD and 
has been recommended over detoxification due to the evidence of longer maternal abstinence, 
higher compliance leading to lower rates of relapse and subsequent fetal illicit drug and 
associated HIV and hepatitis exposure, and better neonatal outcomes.7 However, methadone use 
is highly controlled, requiring its users to visit a treatment center daily and submit to frequent 
urine monitoring. This may be beneficial to patients who require the rigid structure in order to 
maintain discipline but may detract from compliance of those whose daily activities are 
disrupted. Additionally, though it is a preferable alternative to heroin or fentanyl addiction, 
methadone itself is an addictive opioid. Buprenorphine, being a partial mu-agonist that doesn’t 
require the rigidity of methadone administration, can be a more attractive option.5   
In addition to convenience, there are other factors to consider when comparing 
methadone to buprenorphine. In most studies, both methadone- and buprenorphine-exposed 
neonates exhibited NAS requiring pharmacological intervention. However, neonates exposed to 
buprenorphine had lower incidences of NAS, required less medication and lower duration for 
NAS as compared to neonates exposed to methadone.7, 15-18 In some studies that compared the 
two maintenance agonist treatments, it was found that incidences of NAS was comparable 
between buprenorphine and methadone, though there was no mention regarding severity or 
duration of hospital stay. Regarding birth weights, those same review found that birth weights 
were higher for neonates exposed to buprenorphine when compared to those exposed to 
methadone.6, 19 As compared to women who used methadone for OAT, women on buprenorphine 
were more likely to initiate OAT before or during early pregnancy, deliver at full term, have 
longer rates of gestation, and deliver newborns with higher birth weight and bigger head 
circumference.15  
Though most studies showed better neonatal outcomes for neonates exposed to 
buprenorphine, it should be noted that dropout and switch rates from buprenorphine to 
methadone during treatment was higher than the reverse.6, 15, 19 The most cited reason was due to 
suboptimal control of their withdrawal symptoms.15 Attrition rates for buprenorphine treatment 
was generally higher than methadone treatment however, the data indicating reasons why is 
limited as most studies did not track that information. It is an area worth additional research in 
order to guide best practices for appropriate induction and maintenance dosing.7  
Opioid agonist therapy during pregnancy, regardless of which medication is used, is an 
important component of overall maternal, fetal, and neonatal health when compared to 
uncontrolled opioid addiction during pregnancy. While buprenorphine has been shown in 
multiple studies to be at least comparable, and in some cases superior, to methadone in terms of 
neonatal outcomes, all studies concluded that both buprenorphine and methadone are important 
components of treatment for opioid-dependent women at the time of pregnancy.3, 7, 15, 19  
Limitations 
Further research is needed in many areas. Information regarding the effects of maternal 
withdrawal on the fetus would be invaluable in guiding treatment for those who wish to initiate 
naltrexone treatment or detoxification but is very limited due to ethical constraints. Until that 
data is gathered, non-opioid treatment during pregnancy will not be a viable option for most 
mothers despite the superior neonatal outcomes as well as the fact that buprenorphine and 
methadone have quickly become drugs of abuse themselves. The optimal dosing for 
buprenorphine also needs to be studied further as attrition rates for buprenorphine treatment is 
higher than those for methadone, but evidence indicates better neonatal outcomes for mothers 
treated with buprenorphine over methadone. One factor that this study did not take into heavy 
consideration was the multifaceted nature of low birth weights and its other possible 
contributors, such as gestational age at birth, polysubstance abuse, cigarette smoking, and 
alcohol use. However relevant, it was outside the scope of this paper. Lastly, the population of 
affected children has grown due to the opioid epidemic, yielding an opportune time to study the 
long-term effects of OAT. Some areas of interest may be behavioral, psychosocial, and pain 
perception. 
Treatment Recommendations 
Recommendations on treating pregnant women who use opioids or have OUD place 
heavy emphasis on screening. Early universal screening is highly advocated in order to both give 
patients the care they need as well as to give options to women of reproductive age before they 
become pregnant. Universal screening for every pregnant woman should also be conducted 
regardless of their demographic or prior medical and social history to reduce stigma and avoid 
missing cases. There are many recommended screening tools available such as CRAFFT (for 
women 26 years or younger), 4Ps, NIDA Quick Screen.3  
Opioid agonist therapy is the treatment of choice for pregnant women with OUD. The 
outcomes are better for both mother and fetus. It is recommended over medically assisted 
withdrawal or detoxification due to concerns over high relapse rates and the unknown effects of 
withdrawal on the fetus. Behavioral therapy should also be initiated in conjunction with OAT 
and extended into the postpartum period. During prenatal care, the clinician should expand 
treatment to meet the special needs of both mother and fetus including additional fetal 
monitoring to track fetal weight and development as well as additional maternal monitoring for 
diseases common to substance abusers.3  
Monitoring infants born to mothers who used opioids during pregnancy is important 
given the possible subtle presentations of NAS. Infants should be monitored and treated by a 
pediatric care provider. Breastfeeding should be encouraged if the mother is stable on OAT, not 
abusing licit or illicit drugs, and have no other contraindications such as HIV infection. 
Contraceptive counseling should be provided for any woman of reproductive age, particularly 
those who abuse opioids or other drugs to avoid unintended pregnancy. Discussions should be 
had prior to delivery regarding the possibility of long-term contraceptive devices such as an 
intrauterine device which could be inserted immediately after delivery.3  
Conclusion 
 Opioid agonist therapy is the treatment of choice for pregnant women with OUD. 
Neonatal outcomes are better with lower rates of NAS and higher birth weights as compared to 
outcomes for neonates born to mothers with untreated OUD. Medically assisted withdrawal or 
detoxification have high failure rates and put the mother and fetus at risk for continued 
gestational opioid exposure and subsequent poor outcomes.  
 The guidelines that have been outlined can result in high rates of NAS, which can be 
mentally and emotionally draining for all involved. Additionally, the concept of continuing to 
give opioids to people who are addicted to opioids runs counter to intuition as well as the 
precepts of some of the country’s most successful addiction recovery and support groups.20 This 
can influence people who are pregnant to insist on medically assisted withdrawal or 
detoxification. It can also put heavy pressure on the provider to advise their patients of the same. 
However, the data that were investigated for this study show that the nature of opioid addiction 
can often overcome the nature of sheer willpower. Ultimately, NAS is more treatable than 
overdose, severe fetal deformities, or fetal death. As a physician assistant, I will give healthy 
respect to what this study has found and follow the guidelines issued by ACOG. I will advise my 
prepartum and postpartum patients to consider medically assisted withdrawal or detoxification if 
I have assessed that it is appropriate on a case-by-case basis.  
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